OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
Marta Di Forti, Diego Quattrone, Tom P. Freeman, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 5, pp. 427-436
Open Access | Times Cited: 709
Marta Di Forti, Diego Quattrone, Tom P. Freeman, et al.
The Lancet Psychiatry (2019) Vol. 6, Iss. 5, pp. 427-436
Open Access | Times Cited: 709
Showing 1-25 of 709 citing articles:
Schizophrenia
Sameer Jauhar, Mandy Johnstone, Peter J. McKenna
The Lancet (2022) Vol. 399, Iss. 10323, pp. 473-486
Open Access | Times Cited: 547
Sameer Jauhar, Mandy Johnstone, Peter J. McKenna
The Lancet (2022) Vol. 399, Iss. 10323, pp. 473-486
Open Access | Times Cited: 547
Review of the Endocannabinoid System
Hui‐Chen Lu, Ken Mackie
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2020) Vol. 6, Iss. 6, pp. 607-615
Open Access | Times Cited: 362
Hui‐Chen Lu, Ken Mackie
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2020) Vol. 6, Iss. 6, pp. 607-615
Open Access | Times Cited: 362
Cannabis use and cannabis use disorder
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 300
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 300
Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis
Tom P. Freeman, Sam Craft, Jack Wilson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1000-1010
Open Access | Times Cited: 253
Tom P. Freeman, Sam Craft, Jack Wilson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1000-1010
Open Access | Times Cited: 253
Non-Genetic Factors in Schizophrenia
Simona A. Stilo, Robin M. Murray
Current Psychiatry Reports (2019) Vol. 21, Iss. 10
Open Access | Times Cited: 252
Simona A. Stilo, Robin M. Murray
Current Psychiatry Reports (2019) Vol. 21, Iss. 10
Open Access | Times Cited: 252
Associations Between Prenatal Cannabis Exposure and Childhood Outcomes
Sarah E. Paul, Alexander S. Hatoum, Jeremy D. Fine, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 1, pp. 64-64
Open Access | Times Cited: 242
Sarah E. Paul, Alexander S. Hatoum, Jeremy D. Fine, et al.
JAMA Psychiatry (2020) Vol. 78, Iss. 1, pp. 64-64
Open Access | Times Cited: 242
Assessing the public health impacts of legalizing recreational cannabis use: the US experience
Wayne Hall, Michael T. Lynskey
World Psychiatry (2020) Vol. 19, Iss. 2, pp. 179-186
Open Access | Times Cited: 235
Wayne Hall, Michael T. Lynskey
World Psychiatry (2020) Vol. 19, Iss. 2, pp. 179-186
Open Access | Times Cited: 235
The clinical characterization of the patient with primary psychosis aimed at personalization of management
Mario Maj, Jim van Os, Marc D. Binder, et al.
World Psychiatry (2021) Vol. 20, Iss. 1, pp. 4-33
Open Access | Times Cited: 224
Mario Maj, Jim van Os, Marc D. Binder, et al.
World Psychiatry (2021) Vol. 20, Iss. 1, pp. 4-33
Open Access | Times Cited: 224
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Jerome Sarris, Justin Sinclair, Diana Karamacoska, et al.
BMC Psychiatry (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 202
Jerome Sarris, Justin Sinclair, Diana Karamacoska, et al.
BMC Psychiatry (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 202
Cannabis use and psychosis: a review of reviews
Alkomiet Hasan, Rupert von Keller, Chris M. Friemel, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 270, Iss. 4, pp. 403-412
Closed Access | Times Cited: 201
Alkomiet Hasan, Rupert von Keller, Chris M. Friemel, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 270, Iss. 4, pp. 403-412
Closed Access | Times Cited: 201
Neurodevelopmental Resilience and Susceptibility to Maternal Immune Activation
Urs Meyer
Trends in Neurosciences (2019) Vol. 42, Iss. 11, pp. 793-806
Closed Access | Times Cited: 185
Urs Meyer
Trends in Neurosciences (2019) Vol. 42, Iss. 11, pp. 793-806
Closed Access | Times Cited: 185
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 182
Erwin Krediet, Tijmen Bostoen, Joost J. Breeksema, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 23, Iss. 6, pp. 385-400
Open Access | Times Cited: 182
Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis
Guy Hindley, Katherine Beck, Faith Borgan, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 4, pp. 344-353
Open Access | Times Cited: 181
Guy Hindley, Katherine Beck, Faith Borgan, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 4, pp. 344-353
Open Access | Times Cited: 181
Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association
Robert L. Page, Larry A. Allen, Robert A. Kloner, et al.
Circulation (2020) Vol. 142, Iss. 10
Open Access | Times Cited: 179
Robert L. Page, Larry A. Allen, Robert A. Kloner, et al.
Circulation (2020) Vol. 142, Iss. 10
Open Access | Times Cited: 179
‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration
Tom P. Freeman, Valentina Lorenzetti
Addiction (2019) Vol. 115, Iss. 7, pp. 1207-1216
Open Access | Times Cited: 172
Tom P. Freeman, Valentina Lorenzetti
Addiction (2019) Vol. 115, Iss. 7, pp. 1207-1216
Open Access | Times Cited: 172
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Tom P. Freeman, Chandni Hindocha, Gianluca Baio, et al.
The Lancet Psychiatry (2020) Vol. 7, Iss. 10, pp. 865-874
Open Access | Times Cited: 172
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials
Emma Fisher, Andrew Moore, Alexandra E. Fogarty, et al.
Pain (2020) Vol. 162, Iss. 1, pp. S45-S66
Open Access | Times Cited: 168
Emma Fisher, Andrew Moore, Alexandra E. Fogarty, et al.
Pain (2020) Vol. 162, Iss. 1, pp. S45-S66
Open Access | Times Cited: 168
Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
Lindsey A. Hines, Tom P. Freeman, Suzanne H. Gage, et al.
JAMA Psychiatry (2020) Vol. 77, Iss. 10, pp. 1044-1044
Open Access | Times Cited: 160
Lindsey A. Hines, Tom P. Freeman, Suzanne H. Gage, et al.
JAMA Psychiatry (2020) Vol. 77, Iss. 10, pp. 1044-1044
Open Access | Times Cited: 160
Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update
Benedikt Fischer, Tessa Robinson, Chris Bullen, et al.
International Journal of Drug Policy (2021) Vol. 99, pp. 103381-103381
Open Access | Times Cited: 132
Benedikt Fischer, Tessa Robinson, Chris Bullen, et al.
International Journal of Drug Policy (2021) Vol. 99, pp. 103381-103381
Open Access | Times Cited: 132
Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates
Jakob Manthey, Tom P. Freeman, Carolin Kilian, et al.
The Lancet Regional Health - Europe (2021) Vol. 10, pp. 100227-100227
Open Access | Times Cited: 126
Jakob Manthey, Tom P. Freeman, Carolin Kilian, et al.
The Lancet Regional Health - Europe (2021) Vol. 10, pp. 100227-100227
Open Access | Times Cited: 126
Association of cannabis potency with mental ill health and addiction: a systematic review
Kat Petrilli, Shelan Ofori, Lindsey A. Hines, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 9, pp. 736-750
Open Access | Times Cited: 126
Kat Petrilli, Shelan Ofori, Lindsey A. Hines, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 9, pp. 736-750
Open Access | Times Cited: 126
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 59
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 59
THC and CBD: Similarities and differences between siblings
Nephi Stella
Neuron (2023) Vol. 111, Iss. 3, pp. 302-327
Open Access | Times Cited: 54
Nephi Stella
Neuron (2023) Vol. 111, Iss. 3, pp. 302-327
Open Access | Times Cited: 54
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Stefania Bonaccorso, A Ricciardi, Caroline Zangani, et al.
NeuroToxicology (2019) Vol. 74, pp. 282-298
Open Access | Times Cited: 142
Stefania Bonaccorso, A Ricciardi, Caroline Zangani, et al.
NeuroToxicology (2019) Vol. 74, pp. 282-298
Open Access | Times Cited: 142
Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone
Roberto Frau, Vivien Miczán, Francesco Traccis, et al.
Nature Neuroscience (2019) Vol. 22, Iss. 12, pp. 1975-1985
Open Access | Times Cited: 123
Roberto Frau, Vivien Miczán, Francesco Traccis, et al.
Nature Neuroscience (2019) Vol. 22, Iss. 12, pp. 1975-1985
Open Access | Times Cited: 123
